Coinbase published a token sales disclosure for the Monad ICO that contains detailed information about its market maker operators and how many tokens are loaned to each firm. Coinbase’s disclosure may be one of the first cases where a large…Coinbase published a token sales disclosure for the Monad ICO that contains detailed information about its market maker operators and how many tokens are loaned to each firm. Coinbase’s disclosure may be one of the first cases where a large…

Monad ICO loans 160M tokens to five market makers

2025/11/11 18:40
4 min read

Coinbase published a token sales disclosure for the Monad ICO that contains detailed information about its market maker operators and how many tokens are loaned to each firm.

Summary
  • Coinbase revealed full details about Monad’s market maker arrangements, involving Galaxy, GSR, Wintermute and others. The firms will collectively receive 160 million MON in short-term token loans.
  • The Monad ICO, which takes places on Nov. 17, will offer up 7.5 billion MON at a starting price of $0.025. Around 27% of the token supply will be reserved for the team under a multi-year lockup scheme and 38.5% goes to ecosystem development.

Coinbase’s disclosure may be one of the first cases where a large institution fully discloses the list of market makers participating in the initial coin offering for Layer-1 EVM blockchain Monad. The document lays out not only the names of the five market makers involved, but also the scale of funds loaned to each firm and the duration period of each loan.

According to the document, the Monad Foundation subsidiary firm MF Services (BVI), Ltd. has signed token lending contracts with five market makers in the crypto space. The largest loan of MON tokens has been promised to CyantArb, amounting to 50 million MON which will be loaned to the firm for one month.

On the other hand, three market makers will receive a loan of 30 million MON for the duration of one month. These firms are Auros, Galaxy and GSR. Lastly, Wintermute will receive a loan of 20 million MON that it can hold for one year at most.

Information disclosed for market maker agreements regarding Monad ICO | Source: Coinbase

The total amount of tokens allocated to market makers is a combined 160 million MON, which according to its initial set market price of $0.025, will be worth around $4 million.

As stated in the document, the agreements with market makers can be renewed on a monthly basis. The contracts would be monitored by a third-party agency called Coinwatch, which will be responsible for verifying token usage and keeping track of idle balances of the five market makers listed.

In addition, MF Services plan to deploy up to 0.20% of the initial MON token supply for liquidity purposes into one or more decentralized exchange pools. Coinbase deems it a limited short-term effort to facilitate initial token access and stabilize its price in the event of increased market volatility.

Monad ICO to launch with $7.5B tokens on sale

The Monad ICO sale is scheduled to take place on Nov. 17 at 9:00 AM EST and it will end on Nov. 22 at 9:00 AM EST. In total, the project will allocate up to 7.5 billion MON for the token sale or around 7.5% of the initial total supply.

At press time, the project has determined a fixed price of $0.025 for each MON token in the Monad ICO. The market price was determined based on the implied fully diluted value of the Monad Network, which stands at $2.5 billion with an total supply of 100 billion MON tokens.

Based on the document, as much as 27% of the total token supply will be allocated to the team. Team token allocations are subject to both lock-up and vesting conditions. Individual vesting schedules last typically around 3-4 years and are tied to the date of initial involvement in the project.

The document stated that all team tokens will be locked for the first year following the launch of the Monad Public Mainnet and later released during the 1-year anniversary and over the next three years.

Meanwhile, 38.5% tokens will go to the development of the ecosystem. Unlike team tokens, this portion will be unlocked upon launch. Investors will receive up to 19.7%, while 4% will be set aside for the Category Labs treasury, formerly known as Monad Labs. Around 3.3 billion MON or around 3.3% of the initial total supply will go to the airdrop event targeting members of the Monad Community and the wider crypto community following the Monad ICO.

Market Opportunity
TokenFi Logo
TokenFi Price(TOKEN)
$0.003233
$0.003233$0.003233
-0.58%
USD
TokenFi (TOKEN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26